Dopamine agonists in prevention of ovarian hyperstimulation syndrome

References

• Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–7
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112–20
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559–77
   PubMed Web of Science ®Google Scholar
• Fiedler K, Ezcurra D. Predicting and preventing of ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;24:10–32
   Google Scholar
• Papanikolaou EG, Humaidan P, Polyzos N, et al. New algorhitm for prevention of OHSS. Reprod Biol Endocrinol 2011;9:147–50
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Monteleone P, Papini F, Artini PG. Pharmacotherapy of ovarian hyperstimulation syndrome. Expert Opin Pharmacother 2010;11:2527–34
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11
   PubMed Web of Science ®Google Scholar
• Youssef MA, van Vely M, Hassan MA, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010;16:459–66
   PubMed Web of Science ®Google Scholar
• Busso C, Garcia-Velasco J, Gomez R, et al. Symposium: update on prediction and management of OHSS: prevention of OHSS-dopamine agonists. Reprod Biomed Online 2009;19:143–51
   Web of Science ®Google Scholar
• Soares SR, Gomez R, Simon C, et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321–33
   PubMed Web of Science ®Google Scholar
• Fiedler K, Ezcurra D. Predicting and preventing of ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;10:32–7
   PubMed Web of Science ®Google Scholar
• Villasante A, Pacheco A, Pau E, et al. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 2008;23:662–7
   PubMed Web of Science ®Google Scholar
• Rodewald M, Herr D, Duncan WC, et al. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod 2009;24:1191–9
   PubMed Web of Science ®Google Scholar
• Gómez R, Soares SR, Busso C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 2010;28:448–57
   PubMed Web of Science ®Google Scholar
• Basu S, Nagy JA, Vasile E, et al. The neurotransmiter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothealial growth factor. Nat Med 2001;7:569–74
   PubMed Web of Science ®Google Scholar
• Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005;122:127–8
   PubMed Web of Science ®Google Scholar
• Álvarez C, Martí-Bonmatí L, Novela-Maestre E, et al. Dopamine agonist cabergoline reduces haemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–7
   PubMed Web of Science ®Google Scholar
• Carizza C, Abdelmassih S, Ravizzini P, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17:751–5
   PubMed Web of Science ®Google Scholar
• Salah Edeen AMR, Alhelou YM. Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Abstracts of the 25th Annual Meeting of ESHRE; 28 June–1 July 2009; Amsterdam, The Netherlands
   Google Scholar
• Shaltout A, Shohayeb A, Eid M, Abbas S. Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE; 28 June–1 July 2009; Amsterdam, The Netherlands
   Google Scholar
• Tang H, Hunter T, Hu Y, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012;2:CD0086005
   Google Scholar
• Ata B, Seyhan A, Orhaner S, Urman B. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009;92:1168.e1–4
   PubMed Web of Science ®Google Scholar
• Shaltout A, Shohyab A, Youssef MA. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J Obstet Gynecol Reprod Biol 2012;165:254–8
   PubMed Web of Science ®Google Scholar
• Seow KM, Lin YH, Bai CH, et al. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. Reprod Biomed Online 2013;26:562–8
   PubMed Web of Science ®Google Scholar
• Tehraninenjad ES, Hafezi M, Arabipoor A, et al. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 2012;29:259–64
   PubMed Web of Science ®Google Scholar
• Esinler I, Bozdaq G, Karakosokmesuer L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet 2013;288:1159–63
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl Med J 2007;356:29–38
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826–9
   PubMed Web of Science ®Google Scholar
• Izgi C, Feray H, Cevik C, et al. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J Heart Valve Dis 2010;19:797–800
   PubMed Web of Science ®Google Scholar
• Valette S, Semi K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009;12:153–7
   PubMed Web of Science ®Google Scholar
• Drake W, Stiles C, Howlett T, et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 2014;99:90–6
   PubMed Web of Science ®Google Scholar
• Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6–9
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39–46
   PubMed Web of Science ®Google Scholar
• Busso C, Fernández-Sánchez M, García-Velasco JA, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010;25:995–1004
   PubMed Web of Science ®Google Scholar
• Crosignani PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006;125:152–64
   PubMed Web of Science ®Google Scholar
• Spitzer D, Wogatzky J, Murtinger M, et al. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2011;95:2742–4
   PubMed Web of Science ®Google Scholar
• Sherwal V, Malik S, Bhatia V. Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. J Hum Reprod Sci 2010;3:85–90
   PubMedGoogle Scholar
• Baumgarten M, Polanski L, Campbell B, Raine-Fenning N. Do dopamine agonists prevent or reduce the severity ovarian hypestimulation syndrome in women undergoig assisted reproduction? A systematic review and meta-analysis. Hum Fertil (Camb) 2013;16:168–74
   PubMed Web of Science ®Google Scholar
• Soares SR. Etiology of OHSS and the use of dopamine agonists. Fertil Steril 2012;97:517–22
   PubMed Web of Science ®Google Scholar